16033-74-2

Basic information

• Product Name: 4,6-dichloro-N,N-diphenyl-1,3,5-triazin-2-amine
• Synonyms: (4,6-Dichloro-[1,3,5]triazin-2-yl)-diphenyl-amine; 2,4-DICHLORO-6-(DIPHENYLAMINO)-S-TRIAZINE
• CAS NO: 16033-74-2
• Molecular Formula: C₁₅H₁₀Cl₂N₄
• Molecular Weight: 317.1727
• Mol File: 16033-74-2.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 509.2°C at 760 mmHg
• Flash Point: 261.7°C
• Density: 1.414g/cm³
• Vapor Pressure: 1.74E-10mmHg at 25°C
• Refractive Index: 1.674
• CAS DataBase Reference: 4,6-dichloro-N,N-diphenyl-1,3,5-triazin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-dichloro-N,N-diphenyl-1,3,5-triazin-2-amine(16033-74-2)
• EPA Substance Registry System: 4,6-dichloro-N,N-diphenyl-1,3,5-triazin-2-amine(16033-74-2)

Safety Data

• Hazardous Substances Data: 16033-74-2(Hazardous Substances Data)

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 122-39-4 diphenylamine 

Downstream Products

• 1049678-69-4 4-(2-(3-(pyridin-2-yl)-1H-pyrazol-1-yl)ethoxy)-6-chloro-N,N-diphenyl-1,3,5-triazin-2-amine 
• 306315-47-9 C₁₉H₂₁N₇O 

Relevant articles and documents

New triazine bridged triads based on BODIPY-porphyrin systems: Extended absorption, efficient energy transfer and upconverted emission

Two novel triads connecting a BODIPY to ethylenediamine substituted porphyrins via triazine linker have been synthesized and characterized. One of the triads is a linear D-A structure with one BODIPY (D) and one porphyrin (A) bridged by the triazine linke

Organic compound taking triazine and benzimidazole as cores and application thereof

The invention relates to an organic compound taking triazine and benzimidazole as cores and application thereof to an OLED (Organic Light Emitting Diode) device. The compound provided by the invention has relatively high glass transition temperature and m

Docking, synthesis and antimalarial activity of novel 4-anilinoquinoline derivatives

A series of 4-anilinoquinoline triazine derivatives were designed, synthesized and screened for in vivo antimalarial activity against a chloroquine-sensitive strain of Plasmodium berghei. The compounds were further subjected to in vitro antimalarial activity against chloroquine-resistant W2 strain of Plasmodium falciparum and β-haematin inhibition studies. All the compounds exhibited in vivo antimalarial activity better than that shown by the standard drug, chloroquine. Twelve out of fifteen compounds showed better inhibition than that of chloroquine against chloroquine-resistant W2 strain of Plasmodium falciparum. Ten compounds showed β-haematin inhibition, better than that of chloroquine, with IC50 values in the range of 18–25?μM. One compound, 3k, was found to be better than artemisinin against W2 strain of Plasmodium falciparum and also displayed the best β-haematin inhibitory activity, thereby becoming eligible to be explored as a potential lead for antimalarial chemotherapy.